Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

Summary by The Daily News
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct 18, 2025-

3 Articles

The Daily NewsThe Daily News
+2 Reposted by 2 other sources
Center

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Oct 18, 2025-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources are Center
50% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Daily News broke the news in on Saturday, October 18, 2025.
Sources are mostly out of (0)

Similar News Topics

Alameda icon

Alameda

News
For You
SearchBlindspotLocal